Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10211028 | 0.80 | CTSK (0.32) | — | |
| SCHEMBL20166098 | 0.77 | MGAM (0.39) | ALDH1A1LMNAHSD17B10POLBL3MBTL1 | |
| SCHEMBL13630989 | 0.72 | CHRM2 (0.32) | — | |
| SCHEMBL20306165 | 0.71 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10POLBL3MBTL1 | |
| SCHEMBL21081854 | 0.70 | ALDH1A1 (0.36) | ALDH1A1LMNAHSD17B10POLBL3MBTL1 | |
| SCHEMBL28870487 | 0.68 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10POLBL3MBTL1 | |
| SCHEMBL28870488 | 0.68 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10POLBL3MBTL1 | |
| SCHEMBL29128007 | 0.68 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10POLBL3MBTL1 | |
| SCHEMBL24661484 | 0.68 | ALDH1A1 (0.41) | ALDH1A1LMNAHSD17B10POLBL3MBTL1 | |
| SCHEMBL20165506 | 0.68 | MGAM (0.36) | ALDH1A1LMNAHSD17B10POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298867-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R | 2009-12-03 | — | — | US | disclosed |
| US-7589103-B2 | Especially 2-aminocarbonyl-9-(thio)xanthenylidene-8-aza-bicyclo[3.2.1] octane derivatives are used in pharmaceutical and veterinary compositions for treating mild to severe pain and various diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298867-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | ALDH1A1 1302/4885LMNA 4142/4885HSD17B10 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.